Results 21 to 30 of about 180,170 (299)

Second malignancies after multiple myeloma: from 1960s to 2010s. [PDF]

, 2012
To access publisher's full text version of this article. Please click on the hyperlink in Additional Links field.Based on small numbers, recent reports from 3 randomized trials have consistently demonstrated more hematologic malignancies in patients ...
Kristinsson, Sigurdur Y., Turesson, I, Thomas, A, Mailankody, Sham, Korde, Neha, Kristinsson, Sigurdur Y, Turesson, Ingemar, Mailankody, S, Landgren, Ola, Korde, N, Thomas, Anish, Lund University., Landgren, Carl, Turesson, Ingemar,, Kristinsson, SY, Landgren, O   +15 more
core   +1 more source

Multiple Myeloma Case Developed During the Use of the Teriparatide [PDF]

, 2022
Recombinant human parathyroid hormone (1-34) (rhPTH 1-34), teriparatide, is a class of anabolic therapy for treating severe osteoporosis. Although plasma cell dyscrasias are excluded among the known side effects of teriparatide treatment, their ...
Mustafa Ünübol, İrfan Yavaşoğlu, Zehra Erdemir, Ayşe İyiyapıcı Ünübol, Esra Ercan Aktekin, Engin Güney   +5 more
core   +1 more source

Extracellular Vesicles in Hematological Malignancies: From Biomarkers to Therapeutic Tools

Diagnostics, 2020
Small extracellular vesicles (EVs) are a heterogenous group of lipid particles released by all cell types in physiological and pathological states.
Jihane Khalife, James F. Sanchez, Flavia Pichiorri   +2 more
doaj   +1 more source

Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma [PDF]

, 2002
Melphalan is widely used as a preparative agent in patients with multiple myeloma (MM) undergoing autologous stem cell transplantation (SCT). Although disease relapse is the major cause of death after a melphalan-conditioned autograft, the mechanism ...
Mahendra, P, Hochhauser, D, Hockhauser, D, Spanswick, VJ, Shankaranarayana, P, Mahendra, Premini, Hughes, RG, Craddock, Charles; id_orcid, Craddock, C, Sekhar, M, Hartley, JA, Spanswick, V   +11 more
core   +1 more source

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial [PDF]

, 2021
Background In a phase lb study, intravenous daratumumab plus pomalidomide and dexamethasone induced a very good partial response or better rate of 42% and was well tolerated in patients with heavily pretreated multiple myeloma.
Schecter, Jordan M, Moreau, Philippe, Schecter, Jordan M., Terpos, Evangelos, Mateos, Maria Victoria, Bila, Jelena, Boccadoro, Mario, Orfanidis, Ioannis, Mateos, Maria-Victoria, Sonneveld, Pieter, Delimpasi, Sosana, Dimopoulos, Meletios A., Katodritou, Eirini, Dimopoulos, Meletios A, Kampfenkel, Tobias, Symeonidis, Argiris, Vermeulen, Jessica, Qiu, Yanping, Baldini, Luca, Amin, Himal, Ukropec, Jon, BEKSAÇ, MERAL, Ahmadi, Tahamtan, Oriol, Albert, Carson, Robin, Einsele, Hermann   +25 more
core   +1 more source

Blood stem cell collections after mobilization with combination chemotherapy containing ifosfamide followed by G-CSF in multiple myeloma [PDF]

, 2003
High-dose chemotherapy with autologous peripheral blood stem cell transplantation is the standard treatment of patients with multiple myeloma today. In this study we used a combination mobilizing chemotherapy containing ifosfamide with G-CSF before stem ...
Werding, N., Straka, C., Adler-Reichel, S., Emmerich, B., Einsele, H., Hebart, H.   +5 more
core   +1 more source

Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today’s treat-to-target era

Experimental Hematology & Oncology, 2017
B cell lymphoma and multiple myeloma (MM) are the most common hematological malignancies which benefit from therapeutic monoclonal antibodies (mAbs)-based immunotherapies.
Li Zhang, Yu-Tzu Tai, Matthew Zhi Guang Ho, Lugui Qiu, Kenneth C. Anderson   +4 more
doaj   +1 more source

ML-based sequential analysis to assist selection between VMP and RD for newly diagnosed multiple myeloma

npj Precision Oncology, 2023
Optimal first-line treatment that enables deeper and longer remission is crucially important for newly diagnosed multiple myeloma (NDMM). In this study, we developed the machine learning (ML) models predicting overall survival (OS) or response of the ...
Sung-Soo Park, Jong Cheol Lee, Ja Min Byun, Gyucheol Choi, Kwan Hyun Kim, Sungwon Lim, David Dingli, Young-Woo Jeon, Seung-Ah Yahng, Seung-Hwan Shin, Chang-Ki Min, Jamin Koo   +11 more
doaj   +1 more source

Multiple Myeloma [PDF]

Clinical Journal of the American Society of Nephrology, 2006
Multiple myeloma is a malignant disease characterized by plasmacytosis, paraprotein production, bone lesions, hypercalcemia, susceptibility to infections, and renal impairment. The underlying pathophysiologic phenomena of the clinical features include suppression of humoral- and cell-mediated immunity, elevation of IL-6, abnormalities of the bone ...
Seema, Singhal, Jayesh, Mehta
openaire   +5 more sources

Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma

Blood Cancer Journal, 2022
Chimeric antigen receptor T cells (CAR T) are groundbreaking therapies but may cause significant toxicities including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and cytopenias.
Kevin Charles Miller, Patrick Connor Johnson, Jeremy S. Abramson, Jacob D. Soumerai, Andrew J. Yee, Andrew R. Branagan, Elizabeth K. O’Donnell, Anna Saucier, Caron A. Jacobson, Matthew J. Frigault, Noopur S. Raje   +10 more
doaj   +1 more source